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Abstract
Background Emergency treatment of bleeding esophageal varices (BEV) in cirrhotic patients is of prime importance
because of the high mortality rate surrounding the episode of acute bleeding. Nevertheless, there is a paucity of randomized
controlled trials of emergency surgical therapy and no reports of the costs of any of the widely used forms of emergency
treatment. The important issue of direct costs of care was examined in a randomized controlled trial that compared
endoscopic sclerotherapy (EST) to emergency portacaval shunt (EPCS).
Methods Two hundred eleven unselected consecutive patients with ultimately biopsy-proven cirrhosis and endoscopically
proven acute BEV were randomized to EST (n=106) or EPCS (n=105). Diagnostic workup was completed, and EST or
EPCS was initiated within 8 h. Criteria for failure of EST or EPCS were clearly defined, and crossover rescue treatment was
applied, when primary therapy failed. Ninety-six percent of patients underwent more than 10 years follow-up, or until death.
Complete charges for all aspects of care were obtained continuously for more than 10 years.
Results Direct charges for all aspects of care were significantly lower in patients treated by EPCS than in patients treated by
emergency EST followed by long-term repetitive sclerotherapy. Charges per patient, per year of treatment, and per year in
each child’s risk class were significantly lower in patients randomized to EPCS. Charges in patients who failed endoscopic
sclerotherapy and underwent a rescue portacaval shunt were significantly higher than the charges in both the unshunted
sclerotherapy patients and the patients randomized to EPCS. This result was particularly noteworthy given the widespread
practice of using surgical portacaval shunt as rescue treatment only when all other forms of therapy have failed.
Conclusions In this randomized controlled trial of emergency treatment of acute BEV, EPCS was significantly superior to
EST with regard to direct costs of care as reflected in charges for care as well as in survival rate, control of bleeding, and
incidence of portal-systemic encephalopathy. These results provide support for the use of EPCS as a first line of emergency
treatment of BEV in cirrhosis (clinicaltrials.gov #NCT00690027).
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Abbreviations
BEV Bleeding esophageal varices
TIPS Transjugular intrahepatic portosystemic shunt
EST Endoscopic sclerotherapy
EPCS Emergency portacaval shunt
PCS Portacaval shunt
UGI Upper gastrointestinal
ICU Intensive care unit
PRBC Packed red blood cells
PSE Portal-systemic encephalopathy
EVL Endoscopic variceal ligation
QOL Quality of life
RCT Randomized controlled trial
Introduction
Extensive data reported during the past 60 years have
provided clear evidence that bleeding esophageal varices
(BEV) is a common and highly lethal complication of
cirrhosis of the liver.
1 The period surrounding the episode
of acute bleeding has been reported to account for much of
the mortality rate associated with BEV.
1 A number of
modalities of emergency treatment of BEV are in use
including pharmacologic measures, endoscopic therapy,
transjugular intrahepatic portosystemic shunt (TIPS), and
surgical portal decompression. There is no agreement
which of these modalities is most effective, but there is
general agreement that emergency treatment of BEV is of
prime importance. Nevertheless, few randomized controlled
trials of the various modalities of emergency treatment have
been reported. In particular, no randomized trials involving
emergency surgical therapy have been described. Moreover,
little is known about the costs associated with emergency
treatment of BEV, an important measure of the effective-
ness of therapy.
From April 8, 1988, to December 31, 2005, we
conducted a randomized controlled trial (RCT) in 211
unselected consecutive patients with cirrhosis and acute
BEV in whom emergency and long-term repetitive endo-
scopic sclerotherapy (EST) was compared with emergency
direct portacaval shunt (EPCS). The trial was a community-
wide endeavor and was known as the San Diego Bleeding
Esophageal Varices Study. In two recent publications, we
described the study in detail and reported the outcomes first
with regard to control of bleeding and survival,
2 and second
with regard to development of portal-systemic encephalop-
athy (PSE).
3 In a third publication, we compared EPCS to
rescue PCS following failed EST.
4 This report focuses on
direct costs of care.
Patients and Methods
Design of Randomized Controlled Trial
Our two recent publications
2,3 described our RCT and
provided full information on the protocols and methods.
These include (1) design of study; (2) patient eligibility; (3)
definitions (BEV, unselected patients (“all comers”), emer-
gency EST, long-term EST, EPCS, failure of emergency
primary therapy, failure of long-term therapy, rescue
therapy, informed consent); (4) randomization; (5) diagnos-
tic workup; (6) quantitative child’s classification; (7) initial
emergency therapy during workup; (8) endoscopic sclero-
therapy; (9) emergency portacaval shunt; (10) posttreatment
therapy; (11) lifelong follow-up; (12) quantitation of PSE;
(13) data collection. The study protocol and consent forms
were approved before the start of the study and at regular
intervals thereafter by the UCSD Human Subjects Com-
mittee (Institutional Review Board). Figure 1 is a Consort
Flow Diagram that shows the overall design and conduct of
the RCT.
5, 6
Direct Costs of Care
The EST and EPCS groups were compared with regard to
direct costs of care. Complete UCSD charges were obtained
for every patient entered in the RCT. In addition, all
referring hospitals and referring physicians signed agree-
ments to provide complete records of charges as they
occurred. Prior to initiation of the study, UCSD Medical
Center agreed to promptly provide copies of all hospital
and outpatient charges on all patients at the time when the
patients and insurance carriers were billed. Similarly, the
UCSD Medical Group, which does the professional fee
billing for all physicians who care for patients at UCSD
Medical Center, agreed to promptly provide copies of all
professional fee bills. Direct cost of care data were obtained
from April 8, 1988 to November 11, 1999, after which
there were too few survivors of EST to permit a valid
comparison of direct cost data in the two study groups. In
the final analysis, cost of care data from referring hospitals
and non-UCSD physicians were not obtained for 30 of the
627 hospital readmissions (5%) and for 203 of the 4,757
readmission days (4%), equally divided between the EST
and EPCS groups. This small deficiency in data collection
had no influence on the overall results of the analysis.
Sources of healthcare funding or non-funding of all
patients were identified at the time of entry in the study and
J Gastrointest Surg (2011) 15:38–47 39continuously thereafter. Our analysis of direct costs of care
has been accepted for oral presentation at a national
meeting.
Statistical Analysis
The survival times were computed using the Kaplan–Meier
method and were compared between arms using the log-
rank test. Quality of life indices were compared between
arms using Fisher’s exact test (for categorical outcomes)
and Wilcoxon rank-sum test (WRT; for continuous out-
comes). For the charges for care in each category and for
each treatment arm, the mean, standard deviation, and range
(minimum–maximum) were computed. The comparison
between arms used the nonparametric WRT. The charges
per day for index admission were computed by dividing the
index admission charges by the number of days of
hospitalization. The charges per year for post-index
admission and total were obtained by dividing the charges
by the number of years of follow-up. The comparison
between arms used the WRT. The sources of healthcare
funding were compared between arms using Fisher’s exact
test. At the beginning of the study, it was decided in
advance not to perform an interim statistical analysis of the
data, so as not to diminish the power of the final analysis.
Results
Overall Outcome Data of EST versus EPCS
Our recent publications described the clinical characteristics
of the 211 patients, findings on liver biopsy and initial
upper endoscopy, results of laboratory blood tests, data on
rapidity of therapy, data on control of bleeding, operative
and endoscopic data, data on PSE, and data on survival.
2,3
On entry in the RCT the two groups were similar in every
important characteristics of cirrhosis and BEV. Histologic
proof of cirrhosis was obtained in all patients. Mean and
median times from onset of bleeding to entry in the San
Diego BEV Study were less than 20 h in both groups of
patients, and from onset of bleeding to start of EST or
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Fig. 1 The overall design and
conduct of the prospective
randomized controlled trial is
shown in a Consort Flow
Diagram
5,6
40 J Gastrointest Surg (2011) 15:38–47EPCS were less than 24 h. Excluding indeterminate deaths
within 14 days unrelated to bleeding, EST achieved
permanent long-term control of bleeding in only 20% of
patients. In contrast, EPCS promptly and permanently
controlled bleeding in every patient. Patients in the EST
group required significantly more units of PRBC than
those in the EPCS group because of continued or
recurrent BEV. Survival rates at all time intervals and
in all Child’s classes were significantly higher after
EPCS than after EST (p<0.001). Moreover, EPCS
resulted in substantial long-term survival of patients in
child’s risk class C who had the most advanced cirrhosis
of the liver. The incidence of recurrent PSE following
EST was 35%, which was more than twice the 15%
incidence following EPCS (p<0.001). EST patients had a
total of 146 PSE-related hospital admissions, compared
with EPCS patients who had 87 such hospital admissions
(p=0.003). Recurrent UGI bleeding was a major causative
factor of PSE in almost one half of the EST patients.
Direct Costs of Care
Table 1 summarizes the funding sources for all patients in
the San Diego BEV Study. Medi-Cal, which in California is
the form of Medicaid for low-income individuals, was the
most frequent third-party carrier, accounting for 44% of
third-party insurance coverage. A combination of Medi-Cal
and Medicare provided healthcare insurance for 16% of
patients, mainly those whose income was low and who
were age 62 years or older, or had been declared
permanently disabled. Patients whose income was below
the poverty line and had no other healthcare insurance
received coverage in 11% of the cases from San Diego
County Medical Services. Fourteen percent of the patients
had no healthcare insurance and 8% had private insurance.
There were no significant differences in the funding sources
of the two treatment groups. It is important to recognize
that both the charges and actual costs of care were unrelated
to the type of healthcare insurance or non-insurance held by
each patient. For example, all EPCS patients received
identical charges for a portacaval shunt unrelated to
healthcare insurance or non-insurance. Similarly in the
EST group the standard charges for a session of endoscopic
sclerotherapy were not affected by a patient’s health
insurance or non-insurance.
Table 2 and Fig. 2 show the charges for hospitalization
and outpatient care in thousands of US dollars in the EST
and EPCS treatment groups. As expected, the charges for
all aspects of the index admission in patients who
underwent EPCS were significantly greater than the charges
for initial EST (p<0.001). However, these charges were
offset by significantly greater charges for post-index care in
the EST group, in large measure because of recurrent BEV
and the need for repeated readmissions to the hospital. In
the final analysis, the total post-index charges were
significantly greater in patients who were treated by EST
compared to those who underwent EPCS (p<0.001), and
the total overall charges for emergency and long-term care
required over a number of years were greater in patients who
received emergency followed by long-term repetitive EST,
but the difference was not statistically significant (p=0.08).
Note however that the charges in the EPCS group were
spread over a significantly longer period of time.
Table 3 and Fig. 2 show the important relationship
between charges and days or years of required care. When
related to length of survival and, therefore, days or years
during which care was required, EPCS was significantly
less expensive than EST in every aspect of care except for
the index admission. Charges for post-index care per year
in the EST and EPCS groups, respectively, were a mean
$108,500 versus $25,100 (p<0.001). Total overall charges
for care of patients who entered the RCT were a mean
$168,100 per year in the EST group, versus $39,400 per
year in the EPCS group (p<0.001).
Table 4 shows the charges according to Child’s risk
classes assigned at the index admission. Total overall
Table 1 Funding sources for patients in San Diego BEV study
EST (N=106) EPCS (N=105) Total (N=211) P value (EST vs. EPCS)
N % N % N % 0.39
Medi-Cal 41 39 52 50 93 44
Medicare 3 3 6 6 9 4
Medicare/Medi-Cal 18 17 15 14 33 16
Medicare/Private insurance 3 3 3 3 6 3
County medical services 11 10 12 11 23 11
Private insurance 9 8 7 7 16 8
No insurance 20 19 9 9 29 14
VA plus other insurance 1 1 1 1 2 1
J Gastrointest Surg (2011) 15:38–47 41charges per patient were lower in the EPCS group, but the
differences from the EST group were not significant except
in Child’s class C. However, when charges were related to
the more meaningful index of years of required treatment,
mean total charges per year were significantly lower in
patients randomized to EPCS than in those randomized to
EST in all Child’s classes (p=0.004 to <0.001). Since the
EPCS patients lived much longer than the EST patients, the
direct costs were spread over significantly more years and,
therefore, the direct cost per year were much lower.
Table 5 and Fig. 2 compare the charges made to the 50
patients who failed EST and then underwent a rescue PCS,
with the charges made to EST patients who did not have a
rescue PCS and, additionally, with the charges made to
patients in the EPCS group. Compared to EST patients who
did not undergo a rescue PCS, mean total charges in
patients who needed a rescue PCS were significantly higher
per patient (p<0.001) and per year (p=0.02). Moreover,
rescue PCS in the EST group was significantly more costly
than EPCS per patient (p<0.001) and per year (p<0.001).
Discussion
In the San Diego BEV Study, we did not determine actual
costs of care but used charges as an indicator of costs. After
meetings with hospital administrations at UCSD Medical
Center and the referring hospitals, it was made clear that
obtaining actual cost data over the long follow-up period
would not be possible. It was recognized that, as Finkler
has pointed out, “on average charges must exceed costs
because of the need for expansion and replacement of
equipment and facilities,...to cover care to the indigent and
courtesy care; costs of community service; and items
disallowed by Blue Cross, Medicare, and Medicaid”.
7
However, the purpose of our RCT was not so much to
determine the true costs of emergency treatment but to
Table 2 Cost of care charges for hospitalization and outpatient care
Charges in $1,000 EST EPCS P value
N Mean (SD) Range N Mean (SD) Range
Index admission 106 105
Hospital charges 51.3 (52.9) 6.9–433.9 69.1 (56.1) 23.1–352.6 <0.001
a
Physician charges 6.8 (6.6) 1.1–50.4 11.1 (5.4) 3.3–34.8 <0.001
a
Total charges 58.1 (57.3) 8.1–458.5 80.2 (60.0) 33.7–380.5 <0.001
a
Readmission post-index 93 88
Hospital charges 104 (146.2) 0–911.4 56.6 (71.3) 0–262 <0.001
a
Physician charges 15.4 (17.2) 0–89 8.6 (10.5) 0–49.2 <0.001
a
Total charges 119.4 (157.5) 0–926.1 65.2 (80.6) 0–284.2 <0.001
a
Outpatient post-index 93 88
Hospital charges 16.0 (29.7) 0–267.3 8.4 (4.9) 0–27.7 0.17
Physician charges 8.0 (6.6) 0–25.1 6.3 (3.6) 0–12.8 0.29
Total charges 24.0 (33.7) 0–286.9 14.7 (7.6) 0–33.2 0.22
Total post-index 93 143.4 (159.9) 6.2–958.4 88 79.9 (79.8) 0–302 <0.001
a
Total charges 93 194.5 (164.1) 27.5–982.8 88 150.4 (100.8) 41.4–682.5 0.08
After index admission, patients who died during index admission (13 in the EST arm and 17 in the EPCS arm) were excluded
aStatistically significant
Fig. 2 Total charges for patients randomized to endoscopic sclero-
therapy (EST; n=106) or emergency portacaval shunt (EPCS; n=105)
treatment of acutely bleeding esophageal varices
42 J Gastrointest Surg (2011) 15:38–47compare EST versus EPCS. In that comparison, use of
charge data was valid and meaningful. Patients in both
groups received identical charges for all given items of care
such as room rate, ICU rate, laboratory tests, endoscopy,
and so on.
Another aspect of the cost of care which we did not
measure was in the important category of indirect costs due
to mortality and morbidity. These consist mainly of loss of
earnings due to premature death and loss of earnings due to
days lost from work, including days lost from full-time
housekeeping for women. Indirect costs represent a
substantial fraction of the costs of illness and can be
measured by using life tables and data produced by the U.S.
Bureau of the Census and the US Bureau of Labor Statistics
as we have done in the past.
8,9 Because EST, compared to
EPCS in our RCT, had a significantly lower survival rate,
shorter length of survival, and poorer quality of life due to
recurrent BEV, recurrent PSE, and the need for repeated
hospitalization, there can be no doubt that indirect costs of
care were substantially higher in patients treated by EST
than in those who underwent EPCS.
Only four studies of the presumed direct costs of
emergency treatment of BEV have been reported, all of
them involving small numbers of selected patients who
underwent short follow-up. None of the studies determined
the actual costs of care attributable to each individual
patient. In 1984 and 1987, Cello and associates reported the
results of a short-term RCT of emergency treatment of BEV
conducted at a county general hospital.
10,11 EST (n=32)
was compared with EPCS (n=32) in highly selected
patients with what they defined as Child’s class C cirrhosis.
We have commented previously on this trial.
2,3,12 Almost
half of the patients died during the index hospitalization.
Charges for healthcare were used as a surrogate for costs,
and details for obtaining charge data were sketchy. Cello
and associates reported that healthcare charges were similar
in the EST and EPCS treatment groups.
In 1997, Cello and associates reported the results of a
short-term RCT of emergency treatment of BEV in which
EST (n=25) was compared to TIPS (n=24) in highly
selected patients admitted to three hospitals, namely, a
county general hospital, a veterans administration hospital,
and a university teaching hospital.
13 Follow-up information
was obtained through face-to-face interviews, telephone
interviews, or retrospective chart reviews. The costs of
healthcare were determined but, considering the mode of
follow-up, the data were incomplete. Moreover, the three
hospitals differed in the assessment of hospital costs and
professional fees, if any. The authors concluded that
healthcare costs did not differ significantly between the
two treatment groups.
In 1997 and again in 2003, Rosemurgy and colleagues
reported the results of a RCT in which TIPS and H-graft
portacaval shunt were compared in selected patients, most
of whom were treated electively.
14,15 In the 1997 report
only eight patients underwent emergency therapy and in the
2003 report, which was restricted to patients in Child’s
class C, only 13 patients were randomized to emergency
care. Charges were used as a proxy for costs and a number
of significant charges were excluded from the analysis. The
Table 3 Cost of care charges related to time
Charges per day or per year in $1,000 EST EPCS P value
N Mean (SD) Range N Mean (SD) Range
Index admission (per day) 106 105
Hospital charges 3.941 (2.45) 0.83–16.98 5.60 (5.85) 1.98–52.06 <0.001
a
Physician charges 0.66 (1.06) 0.17–10.61 1.05 (1.21) 0.16–7.28 <0.001
a
Total charges 4.60 (2.99) 1.04–19.28 6.65 (6.83) 2.41–58.11 <0.001
a
Readmission post-index (per year) 93 88
Hospital charges 88.4 (210.7) 0–1642 20.4 (48.2) 0–262.3 <0.001
a
Physician charges 12.4 (26.8) 0 180.6 2.6 (5.9) 0–35.8 <0.001
a
Total charges 100.8 (235.7) 0–1832 23.0 (53.6) 0 298.1 <0.001
a
Outpatient post-index (per year) 93 88
Hospital charges 4.9 (6.1) 0–34.3 1.3 (1.2) 0–7.5 <0.001
a
Physician charges 1.9 (2.9) 0–14.7 0.8 (0.5) 0–2.7 <0.001
a
Total charges 7.8 (8.4) 0–48.4 2.1 (1.5) 0–9.5 <0.001
a
Total post-index (per year) 93 108.5 (236.8) 1.5–1824.0 88 25.1 (54.0) 0–302.1 <0.001
a
Total charges (per year) 93 168.1 (320.2) 2.9–1954 88 39.4 (70.4) 2.6–374.5 <0.001
a
After index admission, patients who died during index admission (13 in the EST arm and 17 in the EPCS arm) were excluded
aStatistically significant
J Gastrointest Surg (2011) 15:38–47 43authors concluded in both reports that there was no
significant difference in charges for care between the two
forms of treatment.
In 1999, Gralnek and colleagues reported the economic
impact of endoscopic therapy of BEV in a RCT that
compared EST versus endoscopic variceal ligation (EVL)
in selected patients who had only 1 year of follow-up.
16
Only 21 patients in the study underwent emergency
treatment, and three of these were lost to follow-up, leaving
only 16 patients for analysis of the direct costs of
emergency care. The patients were treated at a veterans
hospital and a university teaching hospital, but the
distribution of patients among these two facilities in which
the costs of care were undoubtedly different, was not
provided. Direct costs for all 16 patients were estimated
from the “UCLA estimated institutional combined fixed
and variable costs for each of the services or procedures
adjusted to the 1995–96 rate.” Professional fee reimburse-
ment was estimated using the 1996 AMA CPT codes and
Medicare fee schedule. The actual costs engendered by
individual patients were not determined. The authors
concluded that median total direct costs and resource
utilization were similar between EST and EVL.
At least 15 studies have been reported in which
hypothetical models have been used to estimate cost of
care of elective treatment aimed at primary prevention or
secondary prophylaxis of BEV. Several recent publications
have summarized these hypothetical studies.
17–19 None of
these studies have included emergency treatment or therapy
by surgery or TIPS. The Markov model and an event
simulation model have been used most widely to calculate
costs of healthcare.
20 The validity of these studies as a
means of determining costs of healthcare is questionable
because the calculations are based on a number of
assumptions extracted from selected studies in the literature
performed by other workers. Conclusions are the result of
calculations, not personal observations, and are dependent
on the accuracy of the reported observations of others.
There has been one recent RCT conducted by Henderson
and colleagues that compared TIPS and distal splenorenal
shunt and included cost of care calculations.
21,22 The RCT
involved 140 highly selected patients with well-
Table 4 Cost of care charges by Child’s class
Charges per day or per year in $1,000 EST EPCS P value
N Mean (SD) Range N Mean (SD) Range
Index admission—total
Child’s class A 32 42.6 (31.7) 13.3–145.0 26 57.6 (21.2) 36.2–146.5 <0.001
a
Child’s class B 46 48.9 (37.6) 8.1–177.5 50 81.8 (62.8) 33.7–380.5 <0.001
a
Child’s class C 28 91.0 (87.7) 21.1–458.5 29 97.5 (72.8) 37.7–337.7 0.25
Post-index—total
Child’s class A 31 151.1 (158.6) 13.5–693.8 25 87.5 (74.6) 12.5–283.5 0.16
Child’s class B 44 144.4 (183.4) 6.2–958.4 45 77.9 (84.3) 0–302.0 0.015
a
Child’s class C 18 127.8 (91.8) 15.9–295.6 18 74.1 (78.8) 10.0–281.6 0.037
a
Total charges per patient
Child’s class A 31 193.5 (159.0) 42.9–712.5 25 145.9 (76.5) 50.3–336.3 0.56
Child’s class B 44 187.8 (182.2) 27.5–982.8 45 149.2 (111.9) 41.4–682.5 0.32
Child’s class C 18 212.6 (129.5) 66.5–563.4 18 159.6 (105.7) 63.4–387.4 0.17
Index admission total/day
Child’s class A 32 3.75 (1.07) 2.25–6.27 26 4.69 (1.20) 2.41–7.61 0.003
a
Child’s class B 46 4.55 (3.28) 1.04–19.28 50 5.94 (4.49) 2.89–33.44 0.001
a
Child’s class C 28 5.65 (3.68) 2.11–16.33 29 9.64 (11.09) 2.86–5811 0.080
Post-index total per year
Child’s class A 31 53.1 (85.0) 1.8–352.3 25 16.1 (25.5) 1.4–125.1 0.003
a
Child’s class B 44 103.3 (159.9) 3.3–736.4 45 28.0 (56.7) 0–251.8 <0.001
a
Child’s class C 18 216.7 (456.1) 1.5–1824.0 18 30.5 (74.3) 1.5–302.1 <0.001
a
Total charges per year
Child’s class A 31 71.2 (100.1) 2.9–437.6 25 26.0 (34.5) 4.9–170.8 0.004
a
Child’s class B 44 187.2 (320.2) 8.0–1674.0 45 44.0 (76.3) 2.6–337.9 <0.001
a
Child’s class C 18 288.3 (494.3) 10.5–1954.0 18 46.3 (90.9) 5.5–374.5 <0.001
a
aStatistically significant
44 J Gastrointest Surg (2011) 15:38–47compensated cirrhosis (Child-Pugh score of nine or less)
who were admitted to five centers that were geographically
distant from each other. The patients underwent TIPS or
distal splenorenal shunt aimed at preventing variceal
rebleeding. Nine hundred nine patients (85%) were exclud-
ed from the RCT and 33 refused to participate. Actual costs
of care, or charges, or reimbursements were not determined.
Cost analysis used diagnosis-related groups (DRG)-based
costs for inpatient events and current processing terminol-
ogy procedures (CPT)-based costs for outpatient events.
National Medicare reimbursements from year 2003 were
used for each DRG, inflated to year 2004 costs using the
medical care inflation index. It was noted that a specific
DRG for TIPS did not exist and had to be estimated based
on Cleveland Clinic data applied to all five centers. Clearly,
all costs of care were not included in the calculations. The
authors concluded that there was no overall significant
difference in the cost of managing these selected good-risk
patients with either TIPS or distal splenorenal shunt.
The results of our RCT of emergency treatment of acute
BEV followed by 9.4 to 10 years or more of follow-up
indicate that direct costs of care as reflected by charges for
all aspects of care were significantly lower in patients
treated by EPCS than in those treated by EST. Overall
charges per patient, charges per year of treatment, and
charges per year in each Child’s risk class were signifi-
cantly lower in patients with BEV randomized to EPCS
than in patients randomized to emergency followed by
long-term repetitive EST.
Of particular note were the charges in patients who failed
ESTand underwent a rescue PCS. Charges for such patients
were significantly higher than the charges required by EST
patients who did not have a rescue shunt as well as by the
patients who underwent EPCS. This finding is noteworthy
because the main use of surgical shunts in recent years in
the USA and abroad has been as elective rescue treatment
for failure of endoscopic therapy and other forms of
treatment of esophageal varices. Our study indicates that
such use of surgical shunts is not only substantially less
effective than EPCS, but also is much more costly.
The reasons why EPCS was less costly than EST are
very likely a consequence of differences in effectiveness of
emergency treatment of BEV. The most important determi-
nants of effectiveness of therapy are survival rate, control of
bleeding, and incidence of recurrent PSE. As we have
observed in our recent reports, compared to EST, EPCS
produced a significantly greater survival rate, was much
more effective in controlling bleeding, and was followed by
less than one half the incidence of PSE.
The effects of EPCS and, therefore, the significantly
lower charges for care, were the result of several critical
aspects of care in our RCT: (1) simplification of the
diagnostic workup so that emergency diagnosis was
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J Gastrointest Surg (2011) 15:38–47 45accomplished entirely at the bedside in a mean 4.4 h; (2)
development of an organized system of pre- and post-
therapy care; (3) a rigorous, lifelong program of follow-up
with intensification of efforts to obtain dietary protein
control and abstinence from alcohol; and (4) permanent
(99%) long-term patency of the portacaval shunt.
As a final note, comment is warranted regarding the use
of EST rather than EVL in this RCT, and the absence of
TIPS. Our use of EST has received strong support from
studies published in 2003, 2005 and 2006 that have
questioned replacement of EST by EVL.
23–26 We discussed
this issue and the justification for our use of EST in our
recent publications.
2,4 It is noteworthy that currently, in our
four-county community of 8.5 million people, gastroenter-
ologists with whom we have had regular and frequent
contact use EST more frequently than EVL. At the time
when EVL was introduced at our institution we were well
into our RCT and made the decision not to change from
EST to EVL.
With regard to TIPS, which was popularized long after
our RCT was initiated, it has become the most widely used
procedure of choice when it is believed that portal
decompression is needed. However, as we have pointed
out previously, TIPS has a high rate of stenosis and
occlusion, a resultant high incidence of PSE, and limited
durability. The TIPS occlusion rate has been reduced by the
recent introduction of the polytetrafluorethylene-coated
stent, but the rates of occlusion and PSE are still much
higher than the incidences of these serious complications
following portacaval shunt in all of our studies. Recently,
we completed a RCT comparing TIPS and EPCS and are in
the process of analyzing the data for publication.
Conclusions
In conclusion, in this RCT of emergency treatment of acute
BEV in 211 unselected, consecutive patients with cirrhosis
of all grades of severity, EPCS resulted in significantly
lower charges for all aspects of care, even when failure of
EST to control bleeding was treated by rescue PCS as
salvage therapy. Charges for EPCS were substantially lower
overall, as well as in relation to days or years of survival,
and in each Child’s class. While charges are not identical to
actual costs, and indirect costs were not determined, it is
reasonable to conclude that the actual costs of EPCS, both
direct and indirect, were significantly lower than the costs
of EST. When added to the other demonstrated benefits of
EPCS, specifically a higher and longer survival rate,
markedly better control of bleeding, and significantly lower
incidence of recurrent PSE, the results of our analysis of
healthcare charges provide support for the use of EPCS as a
first line of emergency treatment of BEV. Moreover, the
results of this RCT raise questions about the widespread
practice of using surgical portal-systemic shunt mainly or
only as salvage therapy for failure of other modalities of
therapy.
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